Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2801501 | 0.82 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL5771282 | 0.81 | CNR1 (0.77) | CNR1CNR2 | |
| SCHEMBL6668995 | 0.80 | CNR1 (0.91) | CNR1CNR2 | |
| SCHEMBL4457218 | 0.77 | CNR1 (1.00) | CNR1 | |
| SCHEMBL5768876 | 0.76 | CNR1 (0.79) | CNR1CNR2 | |
| SCHEMBL5799079 | 0.76 | CNR1 (0.79) | CNR1CNR2 | |
| SCHEMBL5768883 | 0.76 | CNR1 (0.79) | CNR1CNR2 | |
| SCHEMBL5799078 | 0.76 | CNR1 (0.79) | CNR1CNR2 | |
| SCHEMBL5768879 | 0.76 | CNR1 (0.79) | CNR1CNR2 | |
| SCHEMBL5943307 | 0.74 | CNR1 (0.80) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060135523-A1 | 2-substituted 5,6-diaryl-pyrazine derivatives as cb1 modulator | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | US | claimed |
| EP-1641779-A1 | 2-SUBSTITUED 5, 6-DIARYL-PYRAZINE DERIVATIVES AS CB1 MODULATOR. | AstraZeneca AB (SE) | 2006-04-05 | — | — | EP | claimed |
| WO-2004111033-A1 | 2-SUBSTITUED 5, 6-DIARYL-PYRAZINE DERIVATIVES AS CB1 MODULATOR. | ASTRAZENECA AB (SE) | 2004-12-23 | — | — | WO | claimed |
| US-20060135523-A1 | 2-substituted 5,6-diaryl-pyrazine derivatives as cb1 modulator | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135523-A1 | 2-substituted 5,6-diaryl-pyrazine derivatives as cb1 modulator | CNR2, CNR1, GPR55 | CNR1 2/4885CNR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.